
Hundreds of people in England with aggressive blood cancer are set to benefit from an innovative new treatment that reprogrammes a patient’s own immune cells to fight the disease after it was recommended for NHS use.
Lisocabtagene maraleucel – also called liso-cel or Breyanzi and made by Bristol Myers Squibb – has been given the green light by the National Institute for Health and Care Excellence.